References
Cheuk W, Chan JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol. 2010;17:303–32.
Smyrk TC. Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol. 2011;23:74–9.
Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.
Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of novel FAP-targeted radiotracers with improved tumor retention. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.118.224469
Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.
Funding
This work was financially supported by the CAMS Initiative for Innovative Medicine (CAMS-I2M, 2017-I2M-3-001).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was approved by the institutional review board of our hospital, and written informed consent for publication of this report was obtained from the patient.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Image of the month
Rights and permissions
About this article
Cite this article
Luo, Y., Pan, Q. & Zhang, W. IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 46, 2625–2626 (2019). https://doi.org/10.1007/s00259-019-04478-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-019-04478-2